Asarina Pharma has completed a directed share issue raising approximately SEK 48 million to support its therapeutic developments, with participation from notable institutional investors.
Target Company Overview
Asarina Pharma AB (publ) is a biotechnology company listed on the Nasdaq First North Growth Market under the ticker ASAP. The company focuses on advancing innovative therapies for patients with unmet medical needs, particularly in the field of neurological disorders.
Recently, Asarina Pharma has completed a directed share issue, providing the organization with substantial capital to further its research and development initiatives.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Sweden
Sweden is known for its robust biotechnology sector, which is characterized by a high level of innovation and a supportive regulatory environment. The country’
Similar Deals
ANTCO. Investment Group AB (publ) → Deversify AB
2025
ANTCO. Investment Group AB (publ) → Dynamic Code AB (publ)
2025
Asarina Pharma AB
invested in
Asarina Pharma AB
in 2025
in a Other deal
Disclosed details
Transaction Size: $65M